Schedule 13G ownership disclosure

Cumberland Pharmaceuticals, Inc.

Common Stock, no par value · CUSIP: 230770109

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Integrated Core Strategies (US) LLC

    Shares: 598,634.00 · Class: 4.0%

  • Millennium Management LLC

    Shares: 598,634.00 · Class: 4.0%

  • Millennium Group Management LLC

    Shares: 598,634.00 · Class: 4.0%

  • Israel A. Englander

    Shares: 598,634.00 · Class: 4.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-104396
Form type
SCHEDULE 13G/A
Filer
CUMBERLAND PHARMACEUTICALS INC
CIK
CIK 1087294
Filed
Oct 30, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub